Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO’s decision on double patenting, updates from the IP5 meeting on AI patents, and new initiatives by WHO, WTO, and WIPO.
Read more about After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and moreTag: Eli Lilly
Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more
Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates in IP law are discussed, including ongoing litigation and international proposals.
Read more about Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and morePatent Infringement Claim on Cancer Treatment Drug
The UK Court of Appeal ruled that Actavis’s alternative salt forms of pemetrexed would indirectly infringe Eli Lilly’s cancer drug patent. The decision provides insights into patent claim construction and the approach to pharmaceutical patent disputes across multiple European jurisdictions.
Read more about Patent Infringement Claim on Cancer Treatment Drug